FierceBiotech23h
Caris scores FDA approval for multi-cancer companion diagnostic test
across solid tumors with high microsatellite instability status as well as for Keytruda combined with Eisai and Merck’s ...
MedPage Today1d
Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy
Median overall survival (OS) increased from 19.3 months with upfront immune checkpoint inhibition (ICI) to 41.3 months when a ...
Targeted Oncology3d
The Targeted Pulse: A Review of Last Month’s FDA Prominent Actions and Key Data Updates Advancing Treatment Across Disease Types
According to data from the phase 3 double-blinded, active-controlled, multicenter LEAP-012 trial (NCT04246177), lenvatinib (Lenvima) with pembrolizumab (Keytruda) and transarterial chemoembolization ...
Cure Today4d
FDA Approves MI Cancer Seek as Companion Diagnostic for Adult and Pediatric Patients With Cancer
MI Cancer Seek has received approval from the FDA as a companion diagnostic test to identify those who may benefit from ...